All In Biotech

Free tool

FAERS Monitor: Alunbrig

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208772 or its brand name (Alunbrig, Brigatinib). Reports on generic versions are filed under their own applications.

Reports

3,655

Serious

3,259

89% of reports

Hospitalization

1,004

Death reported

788

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death431
  • non-small cell lung cancer396
  • off label use307
  • diarrhoea255
  • metastases to central nervous system242
  • nausea234
  • lung neoplasm malignant225
  • blood creatine phosphokinase increased220
  • fatigue216
  • product dose omission issue204
  • drug ineffective185
  • neoplasm progression180
  • dyspnoea131
  • vomiting130
  • rash124

Reports by year received

View as table
YearReports
20161
201757
2018244
2019310
2020374
2021526
2022579
2023486
2024541
2025377
2026160

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,504 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
non-small cell lung cancerSignal396518.5470.3187,197
metastases to central nervous systemSignal242110.097.325,560
blood creatine phosphokinase increasedSignal22044.339.09,213
lung neoplasm malignantSignal22531.727.96,629
neoplasm progressionSignal18029.926.04,990
product dose omission issueSignal2044.03.5461
deathSignal4312.92.6549
diarrhoeaSignal2552.32.0186
off label useSignal3072.01.8163
nausea2341.71.570
rash1241.61.431
fatigue2161.61.449
vomiting1301.61.329
dyspnoea1311.31.111
drug ineffective1850.80.79

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.